

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Figure 1: Method A:




Figure 2: Method B:




Figure 3: Amorphous particles prior to homogenization (Example 1).




Figure 4: Particles after annealing by homogenization.




Figure 5: X-Ray diffractogram of microprecipitated itraconazole with polyethylene glycol-660 12-hydroxystearate before and after homogenization (Example 5).




Figure 6: Carbamazepine crystals before homogenization (Example 6).





Figure 7: Carbamazepine microparticulate after homogenization (Avestin C-50)



(Example 6).

Figure 8: Diagram of Microprecipitation Process for Prednisolone (Examples 9-12)




Figure 9: Photomicrograph of prednisolone suspension before homogenization  
(Hoffman Modulation Contrast, 1250X magnification)



Figure 10: Photomicrograph of prednisolone suspension after homogenization  
(Hoffman Modulation Contrast, 1250X magnification).




Figure 11: Comparison of size distributions of nanosuspensions (this invention) and commercial fat emulsion. (Example 13)






Figure 12: X-ray powder diffraction patterns for raw material itraconazole (top) and SMP-2-PRE (bottom).  
The raw material pattern has been shifted upward for clarity. (Example 16)




Figure 13a: DSC trace for raw material itraconazole (Example 16)




Figure 13b: DSC trace for SMP-2-PRE. (Example 16)




Figure 14: DSC trace for SMP-2-PRE showing the melt of the less stable polymorph upon heating to 160 °C, a recrystallization event upon cooling, and the subsequent melting of the more stable polymorph upon reheating to 180 °C. (Example 16)




Figure 15: Comparison of SMP-2-PRE samples after homogenization. Solid line = sample seeded with raw material itraconazole. Dashed line = unseeded sample. The solid line has been shifted by 1 W/g for clarity (Example 16)




Figure 16: Effect of seeding during precipitation. Dashed line = unseeded sample, solid line = sample seeded with raw material itraconazole. The unseeded trace (dashed line) has been shifted upward by 1.5 W/g for clarity. (Example 17)




Figure 17: Effect of seeding the drug concentrate through aging. Top x-ray diffraction pattern is for crystals prepared from fresh drug concentrate, and is consistent with the stable polymorph (see Figure 12, top). Bottom pattern is for crystals prepared from aged (seeded) drug concentrate, and is consistent with the metastable polymorph (see Figure 12, bottom). The top pattern has been shifted upward for clarity. (Example 18)




FIG. 18







FIG. 19











FIG. 24

	Sample ID	Particle Size (µm)	Particle Size Distribution	Starch (wt %)	Fast Flow (wt %)	Solid (wt %)	Polysiloxane (wt %)	Starch (wt %)	Fast Flow (wt %)	Starch (wt %)	Starch (wt %)	Starch (wt %)
A	1	40,000	Till Particle Size Plateaus Off	<10	<70	0	0	1.2	8	2.2	5	Yes
B	1	40,000	Till Particle Size Plateaus Off	<10	<70	0	0.03	1.2	8	2.2	5	Yes
C	1	40,000	Till Particle Size Plateaus Off	<10	<70	0.75	0	0	8	2.2	5	Yes

FIG. 25

